How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non- 18F-FDG PET radiopharmaceuticals

Ka Kit Wong, Amanda M. Laird, Amir Moubayed, Sotirios Chondrogiannis, Maria Cristina Marzola, Laura Evangelista, Milton D. Gross, Domenico Rubello

Research output: Contribution to journalArticle

Abstract

Medullary thyroid cancer (MTC) arises from parafollicular C cells and is an elusive tumor to image. It occurs as a sporadic neoplasm in 70-80% of cases and is hereditary in 20-30% because of germline mutations of the rearranged during transfection proto-oncogene. Successful disease management relies on accurate staging. Tumor secretory biomarkers are highly sensitive to a disease; however, despite a wide variety of radiopharmaceuticals for molecular imaging that take advantage of hybrid SPECT/CT and PET/CT fusion imaging, imaging of MTC is still problematic. After initial surgical resection, the limited sensitivity of localization of small locoregional disease and the inability to detect early liver metastases hamper the success of later surgical approaches. 18F-fluorodeoxyglucose PET has been used to detect MTC recurrences with modest success and may be best suited for only a small subset of more biologically aggressive MTCs. Recent developments in PET imaging with novel radiopharmaceuticals targeting specific cellular processes of MTC offer increased sensitivity for identifying recurrence, assessing prognosis, and guiding selection of optimal therapies.

Original languageEnglish
Pages (from-to)679-688
Number of pages10
JournalNuclear Medicine Communications
Volume33
Issue number7
DOIs
Publication statusPublished - Jul 2012

Keywords

  • F- fluorodeoxyglucose
  • F-fluorodihydroxyphenylalanine
  • conventional imaging
  • medullary thyroid cancer
  • PET
  • restaging
  • staging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'How has the management of medullary thyroid carcinoma changed with the advent of <sup>18</sup>F-FDG and non- <sup>18</sup>F-FDG PET radiopharmaceuticals'. Together they form a unique fingerprint.

  • Cite this